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Abstract
Objective To compare the prevalence of factor V Leiden
(FVL) and prothrombin (PT) G20210A mutations in Por-
tuguese women with unexplained recurrent miscarriage
(RM) and a control group of parous women.
Materials and methods FVL and PT G20210A analysis
were carried out in 100 women with three or more con-
secutive miscarriages and 100 controls with no history of
pregnancy losses. Secondary analysis was made regarding
gestational age at miscarriage (embryonic and fetal losses).
Results Overall, the prevalence of FVL and PT G20210A
was similar in women with RM (5 and 3%) compared with
controls (5 and 1%) OR 1.36 (CI 95% 0.45–4.08). In RM
embryonic subgroup, PT G20210A was observed in 1.3%
of women and FVL prevalence (2.6%) was inclusively
lesser than that of controls. Both polymorphisms were
more prevalent in women with fetal losses than in controls,
although statistical significance was not reached due to the
small size of the [10 weeks’ subgroup.
Conclusion These data indicate that neither FVL nor PT
G20210A is associated with RM prior to 10 weeks of
gestation. Therefore, its screening is not indicated as an
initial approach in Portuguese women with embryonic RM
and negative personal thromboembolic history.
Keywords Factor V Leiden  Prothrombin G20210A 
Recurrent miscarriage
Introduction
One per cent of women in the reproductive age group
experience recurrent miscarriage (RM), three or more
clinically recognized pregnancy losses before 22nd gesta-
tional week [1–3]. RM is one of the most disturbing
women’s health issues and several medical factors (chro-
mosomal, anatomic, autoimmune, and metabolic disorders)
have been reported as possible causes [4–8]. However,
after standard investigations, up to 50% of these cases
remain unexplained [2, 9, 10].
Thrombophilia is the main risk factor for maternal
thromboembolism. Data accumulated over the past two
decades have established a clear association between an-
tiphospholipid syndrome (APS), an acquired thrombophilic
state, and RM [11–15]. Recent investigations have focused
on a higher prevalence of certain inherited thrombophilias,
such as factor V Leiden (FVL) and prothrombin (PT)
G20210A mutations, in women with unexplained recurrent
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pregnancy losses [16–21]. Nevertheless, these reports have
produced conflicting results [22–25] and this heterogeneity
is reflected in existing meta-analyses [17, 20, 26, 27].
The relative preponderance of particular type of
thrombophilic gene may depend on the patient’s ethnic
origin, altering the relative importance of thrombophilic
marker as a cause of RM [28]. In 1994, it was first
described that FVL is the genetic risk factor for thrombosis
more prevalent in humans [29]. This polymorphism is
relatively common among the Caucasian population,
ranging from 1 to 10% in different geographic regions
[26–30]. PT G20210A, the second most frequently inher-
ited thrombophilia, is present in 1 to 3% of the Europeans
[31]. In Mediterranean countries, prevalence of 5 and 2%,
respectively for these mutations were described [32].
Together with ethnicity, other confounding factors, such
as the specification of the gestational age of pregnancy
losses and the inclusion of patients with known causes of
RM, have led to heterogeneous results in existing studies,
and point to the need for more uniform research before
inclusion of these exams in RM etiological investigation.
However, two recent studies conducted in the USA and in
the UK, exploring practice patterns of obstetricians,
showed that a large proportion of clinicians include heri-
table thrombophilia in RM initial investigation. The
majority (70–80%) of the respondents tests patients rou-
tinely for FVL and 50% for PT G20210A. About 80%
of the women who tests positive start antithrombotic
therapy with AAS and/or heparin in subsequent pregnan-
cies [33, 34].
The prevalence of FVL and PT G20210A in Portuguese
women with RM has not yet been studied. Therefore, the
purpose of this study was to assess the association between
these two hereditary thrombophilias and RM in our
population.
Materials and methods
Participants
The study population comprised 100 consecutive women
with unexplained RM, referred for evaluation at the
Recurrent Miscarriage Clinic at Maternidade Dr. Alfredo
da Costa, Lisbon, and 100 matched controls.
In the study group, eligibility criteria were the existence
of three or more consecutive pregnancy losses before
22nd week, regardless of a previous live birth. Patients
were included in the study only if the conventional etio-
logical factors for RM (parental chromosomal abnormali-
ties, uterine structural abnormalities or APS) were found to
be normal. Women under the age of 18 or above 40 years
were excluded.
The control group consisted of 100 age-matched women
with at least one child alive and without history of preg-
nancy losses or other gestational complication. The control
group also matched to the ethnic origin of the patients.
All women with a history of thromboembolic events
were excluded from this study (Table 1).
The average number of losses of the RM group was 3.43
per woman (min 3–max 6). The majority (77%) had suf-
fered embryonic losses (\10th gestational weeks) and 23
had at least one fetal loss (11–22 weeks). Sixty-one were
nulliparous (primary miscarriage) and the remaining 39
had at least one previous live birth. Controls had an aver-
age of 1.6 children (DP = 0.67; min 1–max 3). Ninety-
three percent of women in each group were Caucasian.
Women with RM were slightly older (M = 32 years) than
those of the control group (M = 30.9 years), although this
difference was not significant (t = -1.698; df = 198;
p = 0.091).
The demographic details and outcome of previous
pregnancies of these women are shown in Table 2.
Laboratory procedure
Blood samples were collected in sodium citrate from all
women and double centrifuged. Platelet-poor plasma
obtained was separated, tested for prothrombin time and
partial thromboplastin time and frozen at -20C. After
plasma separation, the resulting cells were stored at
-20C. Screening for FVL was made through the resis-
tance to activated protein C (RPCa), using the kit He-
mosil Factor V Leiden (APCTM Resistance V),
Instrumentation Laboratory, Italy. A cutoff value of 2.1
was considered, and all samples with higher value were
Table 1 Inclusion and
exclusion criteria of patients
and controls
RM women Controls
Inclusion criteria C3 consecutive miscarriages C1 living birth without pregnancy losses
Exclusion criteria \18 [40 years Previous thromboembolism
Previous thromboembolism Previous miscarriage or other gestational
complicationAbnormal parental karyotype
Uterine structural abnormalities
Antiphospholipid syndrome
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considered negative for the presence of FVL. DNA was
extracted and isolated through automatic method of solid
phase, according to the manufacturer’s instructions (EZ1
200 ll blood DNA Kit used with Biorobot EZ1, both of
Qiagen, Germany). Molecular diagnosis of FVL and PT
G20210A mutations was performed by reverse hybrid-
ization of DNA amplification by PCR products using
allele-specific oligonucleotide probes (PTH StripAssay
kits and FV StripAssay, ViennaLab Diagnostics GmbH,
Austria).
Ethics
The study was approved by the Ethical Committee of the
Hospital. Informed consent was obtained from each
woman.
Statistical analysis
Data were expressed in the form of mean ± SD and per-
centages as appropriate. To compare the groups on cate-
gorical variables, Chi square test (v2) was used and, when
the expected frequencies were lesser than five, it was
replaced by the likelihood ratio Chi square test (G test), as
recommended by Agresti [35] and O¨zdemir and Eyduran
[36]. For comparison between the two means, an inde-
pendent Student’s t test was performed. The magnitude of
association odds ratio (OR) and their confidence intervals
(CI) to 95% were calculated by logistic regression. The
statistical analysis was carried out in the program SPSS
version 15 (Inc., Chicago, IL), considering a significance
level of 5%.
Results
An abnormal thrombophilic genotype was found in a
similar percentage (8% vs. 6%) among women with RM
and healthy controls (Table 3). However, the prevalence of
FVL was equal among patients and controls (5%); PT
G20210A was more frequent in RM women, although this
difference was not significant (3% vs. 1%) OR 3.06
(CI 95% 0.31–29.94). There was no detected double carriage
of the mutations in our investigated group of women. All
heterozygous for FVL occurred in the Caucasian women.
When analyzed separately, carriage of these mutations
was found in 3 of 77 women (3.9%) with embryonic losses
and in 6% of the controls OR 0.64 (CI 95% 0.15–2.63;
p [ 0.05). In this group of women, the prevalence of FVL
was inclusively inferior in patients (2.6%) compared to
controls (5%) (Table 3).
In 5 out of the 23 the women with fetal losses (21.7%) a
polymorphism was identified (Table 3). The prevalence of
both FVL (13%) and PT G20210A (8.7%) in this subgroup
of women was much more pronounced than in the control
group (5 and 1%, respectively).
Ethnicity or parity did not influence our results in either
embryonic or fetal losses subgroups.
Discussion
In our study, no difference was found in the prevalence of
these two polymorphisms among women with RM and a
control group of healthy parous women. Similar results
have been reported by Dilley et al. [23] in a controlled
Table 2 Population
characteristics
RM total
(n = 100)
Embryonic losses
(n = 77)
Fetal losses
(n = 23)
Controls
(n = 100)
Median age (mean ± SD) 32 ± 4.25 31.9 ± 4.27 32 ± 4.23 30.9 ± 5.19
Ethnics
Caucasian 93 73 (94%) 20 (87%) 93
Black 7 4 (57%) 3 (43%) 7
Nulliparous 61 (61%) 48 (62%) 13 (57%) –
Miscarriages (mean ± SD) 3.43 ± 0.67 3.40 ± 0.67 3.52 ± 0.66 –
Table 3 Prevalence of FVL and PT G20210A in patients and controls
Controls RM total Embryonic losses Fetal losses
n = 100 (%) n = 100 (%) p n = 77 (%) p n = 23 (%) p
Heterozygous FVL 5 (5) 5 (5) 1.0 2 (2.6) 0.406 3 (13) 0.195
Heterozygous PT G20210A 1 (1) 3 (3) 0.302 1 (1.3) 0.853 2 (8.7) 0.065
Total 6 (6) 8 (8) 3 (3.9) 5 (21.7)
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study conducted in 60 women with RM and 92 parous
controls. Two prospective multicenter studies, involving
each over 4,000 first trimester pregnant women, did not
find an increased miscarriage rate in carriers of these
mutations [37, 38]. A European prospective research,
conducted in women with a previous miscarriage, has also
found a similar outcome between subsequent pregnancies
of FVL and PT G20210A carriers and noncarriers [22].
However, other studies revealed discordant results and
clinicians continue to incorporate these tests in RM
investigation protocol [17, 21, 26, 33, 34].
Some methodological aspects such as inclusion in
studies of participants with other potential underlying
causes of RM, the lack of stratification of cases by
women’s ethnicity and gestational age of losses, may have
impaired the quality of the available data [26].
RM is a multifactorial entity and the great variation in
the strength of this association found in most studies may
indicate the presence of additional risk factors. To diminish
this type of potential biases, in our research, only cases of
unexplained RM were considered.
Gestational age of the losses may also influence the
strength of this association. Clinical miscarriage is an entity
that covers a wide period of time which extends from the
biochemical identification of pregnancy until the 22nd
week, and different pathophysiological mechanisms may be
responsible for pregnancy loss. For this reason, many authors
have chosen to examine separately the impact of hereditary
thrombophilia on each trimester of pregnancy. Controlled
studies conducted in the European Caucasian women with a
history of unexplained RM failed to demonstrate an associa-
tion between these two polymorphisms and 1st trimester RM
[19, 39]. The meta-analyses that have adopted this method-
ology has also revealed a higher ratio of FLV related losses
after the 14th week (OR 2.28) compared with 1st trimester
RM (OR 1.6–1.91) [20, 26, 27, 40].
Factor V plays an important role in cell adhesion, pro-
liferation of smooth muscle and vasculogenesis during
embryonic development, and a possible beneficial effect of
FVL, due to facilitation in embryonic implantation, had
already been suggested by Majerus and Roque et al.
[41–43]. According to this hypothesis, an increase in
implantation rate has been reported in pregnancies result-
ing from intracytoplasmatic sperm injection, in situations
where the mother and/or fetus were carriers of FVL [44]. A
recent study, conducted by Ivanov et al. [45] in the Cau-
casian women with unexplained RM, has consolidated
these results. These authors found a similar prevalence of
FVL (9.6 vs. 7%) in women with embryonic losses and
controls OR 1.41 (CI 95% 0.45–4.41). On contrary, in the
group of women who suffered losses between 10 and
14 weeks of gestation, the prevalence of FVL (18.6%) was
much more pronounced OR 3.05 (CI 95% 1.01–9.38,
P = 0.047). Our results are also in line with those of this
study, and while among women with embryonic losses
FVL prevalence (2.6%) was even lesser than that of con-
trols (5%) OR 0.50 (CI 95% 0.09–2.68), in women with
fetal losses this prevalence (13%), though not significant,
was substantially higher OR 2.85 (0.63–12.9).
Most of the scientific evidence that associates PT
G20210A mutation to pregnancy failure originates in case–
control studies [24, 25, 46]. These studies, as those carried
out on the FLV, are subject to bias and may overstate its
impact on obstetric outcome [38]. Nevertheless, in most
investigations, this relationship is consistent and, as descri-
bed for FLV, is weaker with 1st trimester compared with 2nd
trimester RM [17, 20, 27]. In the study of Ivanov et al. [45],
the prevalence of PT20210A was higher in women with both
embryonic (17%) and fetal (16.9%) losses compared with
controls (3%). Our results also showed an increased preva-
lence of this polymorphism in RM women, particularly
patent in those with fetal miscarriages. However, the reduced
size of this subgroup of patients (n = 23) does not allow us to
establish any secure association.
The main limitation of our investigation relates to the
dimension of our population and a larger study might
clarify some interpretations.
Conclusions
The impact of heritable thrombophilia on RM remains a
controversial issue and recent investigations have sparked
the uncertainty about the existence of a causal relationship
between these two entities [47–51]. Our data reinforce the
results of previous research and indicate that FVL and
PTG20210 are not associated with pregnancy wastage prior
to 10 weeks of gestation. Although these polymorphisms
were more prevalent in women with fetal losses, overall,
our results do not support their screening as an initial
approach in the Portuguese women with RM and a negative
personal history of thromboembolism.
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